About Nucleic acid dioxygenase ALKBH1
Nucleic acid dioxygenase ALKBH1 (ALKBH1) is a protein
from Homo sapiens identified by UniProt accession
Q13686, 389 residues long.
MolForge cross-references it against 0 known binders and
169 disease associations.
Target properties
| Protein name | Nucleic acid dioxygenase ALKBH1 |
|---|
| UniProt accession | Q13686 |
|---|
| Gene | ALKBH1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 389 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (169)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.15
- cancer · score 0.08
- gastric adenocarcinoma · score 0.08
- lung adenocarcinoma · score 0.08
- glioblastoma multiforme · score 0.08
- hepatocellular carcinoma · score 0.08
- neoplasm · score 0.07
- Hepatic steatosis · score 0.07
- head and neck squamous cell carcinoma · score 0.07
- gonorrhea · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q13686-F1 | alphafold | PREDICTED | 86.00 | — |
Amino-acid sequence (389 residues)
MGKMAAAVGS VATLATEPGE DAFRKLFRFY RQSRPGTADL EGVIDFSAAH AARGKGPGAQ KVIKSQLNVS SVSEQNAYRA GLQPVSKWQA YGLKGYPGFI FIPNPFLPGY QWHWVKQCLK LYSQKPNVCN LDKHMSKEET QDLWEQSKEF LRYKEATKRR PRSLLEKLRW VTVGYHYNWD SKKYSADHYT PFPSDLGFLS EQVAAACGFE DFRAEAGILN YYRLDSTLGI HVDRSELDHS KPLLSFSFGQ SAIFLLGGLQ RDEAPTAMFM HSGDIMIMSG FSRLLNHAVP RVLPNPEGEG LPHCLEAPLP AVLPRDSMVE PCSMEDWQVC ASYLKTARVN MTVRQVLATD QNFPLEPIED EKRDISTEGF CHLDDQNSEV KRARINPDS
Explore Nucleic acid dioxygenase ALKBH1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets